Maternal LAMP/p55gagHIV-1 DNA Immunization Induces In Utero Priming and a Long-Lasting Immune Response in Vaccinated Neonates
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
MACIEL JR., Milton
GOLDONI, Adriana Leticia
PIUBELLI, Orlando Guerra
MARQUES, Ernesto Torres
AUGUST, Joseph Thomas
Citação
PLOS ONE, v.7, n.2, article ID e31608, 11p, 2012
Resumo
Infants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been shown to enhance anti-Gag antibody (Ab) and cellular immune responses in adult and neonatal mice; such a vaccine represents a new concept in antigen presentation. In this study, we evaluated the effect of LAMP/gag DNA immunization on neonates either before conception or during pregnancy. LAMP/gag immunization of BALB/c mice before conception by the intradermal route led to the transfer of anti-Gag IgG1 Ab through the placenta and via breastfeeding. Furthermore, there were an increased percentage of CD4+ CD25+ Foxp3+ T cells in the spleens of neonates. When offspring were immunized with LAMP/gag DNA, the anti-Gag Ab response and the Gag-specific IFN-gamma-secreting cells were decreased. Inhibition of anti-Gag Ab production and cellular responses were not observed six months after immunization, indicating that maternal immunization did not interfere with the long-lasting memory response in offspring. Injection of purified IgG in conjunction with LAMP/gag DNA immunization decreased humoral and cytotoxic T-cell responses. LAMP/gag DNA immunization by intradermal injection prior to conception promoted the transfer of Ab, leading to a diminished response to Gag without interfering with the development of anti-Gag T- and B-cell memory. Finally, we assessed responses after one intravenous injection of LAMP/gag DNA during the last five days of pregnancy. The intravenous injection led to in utero immunization. In conclusion, DNA vaccine enconding LAMP-1 with Gag and other HIV-1 antigens should be considered in the development of a protective vaccine for the maternal/fetal and newborn periods.
Palavras-chave
Referências
- Arruda LB, 2006, J IMMUNOL, V177, P2265
- Becquet R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007397
- BOGEN B, 1993, EMBO J, V12, P357
- Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486
- de Alencar BCG, 2009, INFECT IMMUN, V77, P4383, DOI 10.1128/IAI.01459-08
- De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
- de Brito CA, 2009, IMMUNOTHERAPY, V1, P883, DOI [10.2217/imt.09.38, 10.2217/IMT.09.38]
- Fusaro AE, 2002, INT ARCH ALLERGY IMM, V127, P208, DOI 10.1159/000053865
- Fusaro AE, 2007, IMMUNOLOGY, V122, P107, DOI 10.1111/j.1365-2567.2007.02618.x
- Fusaro AE, 2009, IMMUNOLOGY, V128, pe541, DOI 10.1111/j.1365-2567.2008.03028.x
- Gerdts V, 2000, NAT MED, V6, P929
- Goldoni AL, 2011, IMMUNOBIOLOGY, V216, P505, DOI 10.1016/j.imbio.2010.08.007
- Hassett DE, 1997, J VIROL, V71, P7881
- Horwitz DA, 2008, EUR J IMMUNOL, V38, P912, DOI 10.1002/eji.200738109
- John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918
- JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116
- Kanwar B, 2010, CURR OPIN HIV AIDS, V5, P151, DOI 10.1097/COH.0b013e328335c0c1
- Kim J, 2009, J IMMUNOL, V182, P2583, DOI 10.4049/jimmunol.0803247
- Lohman-Payne B, 2010, CLIN PERINATOL, V37, P787, DOI 10.1016/j.clp.2010.08.005
- Manickan E, 1997, J CLIN INVEST, V100, P2371, DOI 10.1172/JCI119777
- Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
- Victor JR, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-11
- Okuda K, 2001, J IMMUNOL, V167, P5478
- Rigato PO, 2010, VIROLOGY, V406, P37, DOI 10.1016/j.virol.2010.06.050
- Rigato PO, 2009, IMMUNOTHERAPY, V1, P141, DOI [10.2217/1750743X.1.1.141, 10.2217/1750-743X.1.1.141]
- Rinaldi M, 2006, VACCINE, V24, P4586, DOI 10.1016/j.vaccine.2005.08.030
- Sedegah M, 2003, J IMMUNOL, V171, P3148
- Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004
- Siegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.3.CO;2-C
- UNAIDS, 2009, AIDS EP UPD
- Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39
- Xin Ke-Qin, 2002, Biological Procedures Online, V3, P91, DOI 10.1251/bpo27
- Xin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356